UK markets open in 1 hour 17 minutes
  • NIKKEI 225

    28,501.14
    -599.24 (-2.06%)
     
  • HANG SENG

    28,650.16
    -485.57 (-1.67%)
     
  • CRUDE OIL

    62.61
    +0.17 (+0.27%)
     
  • GOLD FUTURES

    1,783.50
    +5.10 (+0.29%)
     
  • DOW

    33,821.30
    -256.33 (-0.75%)
     
  • BTC-GBP

    39,726.85
    +104.82 (+0.26%)
     
  • CMC Crypto 200

    1,271.25
    +36.83 (+2.98%)
     
  • ^IXIC

    13,786.27
    -128.50 (-0.92%)
     
  • ^FTAS

    3,920.05
    -76.60 (-1.92%)
     

Zealand Pharma to participate in upcoming investor conferences

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zealand Pharma
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Company announcement – No. 17 / 2020

Zealand Pharma to participate in upcoming investor conferences

Copenhagen, DK and Boston, MA, U.S. March 25, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in April:

Guggenheim Virtual Healthcare Talks - Genomic Medicines & Rare Disease

Date: Thursday, April 1, 2021

20th Annual Virtual Needham Healthcare Conference

Date: Monday, April 12, 2021

Presentation: 11:45 a.m. ET/ 4:45 p.m. CET


A live webcast of the Needham event will be available on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations. A replay of the webcast will be archived on the Company's website following the presentation.

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics. Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

For further information, please contact:

Zealand Pharma Investor Relations
Claudia Styslinger
Argot Partners
investors@zealandpharma.com

Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com